Substance
EVOLOCUMAB
Global reference: every product and company linked to this substance.
- cas: 1256937-27-5
- ncit: C174672
- rxnorm: 1665684
- unii: LKC0U3A8NJ
AMG-145 · EVOLOCUMAB (GENETICAL RECOMBINATION) · evolocumab [INN] · EVOLOCUMAB [JAN] · EVOLOCUMAB [USAN] · Evolocumab [WHO-DD] · REPATHA
Revenue by product (2)
| Company | Product | Latest period | Revenue |
|---|---|---|---|
| AMGEN INC. COMMON STOCK | REPATHA | Q2 2026 | $953.0M |
| AMGEN INC. COMMON STOCK | REPATHA | Q2 2026 | $953.0M |
A figure belongs to the product it was reported for. It is never summed across companies or across a company's products, so one substance in three products shows three figures.
Products containing this substance (2)
- REPATHA · AMGEN INC. COMMON STOCK
- REPATHA · AMGEN INC. COMMON STOCK